Acorda Therapeutics Competitors

Acorda Therapeutics (NASDAQ:ACOR) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

75.2% of Amgen shares are held by institutional investors. 6.8% of Acorda Therapeutics shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Acorda Therapeutics and Amgen's net margins, return on equity and return on assets.

Volatility & Risk

Acorda Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Acorda Therapeutics and Amgen, as provided by MarketBeat.

Acorda Therapeutics currently has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Amgen has a consensus target price of $256.0909, suggesting a potential upside of 13.86%. Given Acorda Therapeutics' higher possible upside, equities analysts clearly believe Acorda Therapeutics is more favorable than Amgen.

Earnings & Valuation

This table compares Acorda Therapeutics and Amgen's revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Acorda Therapeutics on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Gilead Sciences and Acorda Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and Acorda Therapeutics, as reported by MarketBeat.com.

Gilead Sciences presently has a consensus target price of $96.0370, suggesting a potential upside of 56.41%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Gilead Sciences.

Valuation and Earnings

This table compares Gilead Sciences and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Acorda Therapeutics on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Vertex Pharmaceuticals and Acorda Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Acorda Therapeutics, as reported by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, suggesting a potential upside of 37.31%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Acorda Therapeutics on 13 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Acorda Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Regeneron Pharmaceuticals and Acorda Therapeutics, as reported by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus target price of $625.8077, suggesting a potential upside of 38.89%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Acorda Therapeutics on 13 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Acorda Therapeutics (NASDAQ:ACOR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Biogen and Acorda Therapeutics, as reported by MarketBeat.com.

Biogen presently has a consensus target price of $304.4667, suggesting a potential upside of 11.58%. Acorda Therapeutics has a consensus target price of $23.6667, suggesting a potential upside of 306.64%. Given Acorda Therapeutics' higher possible upside, analysts clearly believe Acorda Therapeutics is more favorable than Biogen.

Volatility and Risk

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Profitability

This table compares Biogen and Acorda Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

83.5% of Biogen shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 6.8% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Biogen and Acorda Therapeutics' revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Acorda Therapeutics on 11 of the 14 factors compared between the two stocks.

Acorda Therapeutics (NASDAQ:ACOR) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Acorda Therapeutics and Alexion Pharmaceuticals, as reported by MarketBeat.

Acorda Therapeutics presently has a consensus price target of $23.6667, suggesting a potential upside of 306.64%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 0.25%. Given Acorda Therapeutics' higher possible upside, equities analysts plainly believe Acorda Therapeutics is more favorable than Alexion Pharmaceuticals.

Risk & Volatility

Acorda Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Acorda Therapeutics and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 6.8% of Acorda Therapeutics shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Acorda Therapeutics and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Acorda Therapeutics on 12 of the 15 factors compared between the two stocks.